Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Multiple sclerosis: pathogenesis and treatment.
Interleukin-1beta promotes repair of the CNS.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Neuroprotective effects of resident microglia following acute brain injury.
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Firategrast
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Dimethyl fumarate for multiple sclerosis.
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
European School of Neuroimmunology 15th Course

Pages